To our knowledge, the only published study that analyzed the role of CDKN2A in ICB resistance in NSCLC found a non-significant trend between CDKN2A LOF status and OS (WT vs. LOF, OS HR 1.3, p = 0.11). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.